


New anti-adhesion drug against *Pseudomonas aeruginosa*



Ref. Nr

6.2480

Keywords

Pseudomonas aeruginosa,
cystic fibrosis, anti-
adhesive therapy, antibiotic
resistance

Intellectual Property

EP2418668.6 priority
07.06.2024

Publications

-

Date

15/04/2025

Description

Pseudomonas aeruginosa is a highly virulent pathogen known for causing severe infections both in acute and chronic cases, especially in the lungs. *P. aeruginosa* commonly transitions from a planktonic to surface-adapted lifestyle to initiate infection. *P. aeruginosa* senses surface contact and in response, it improves adhesion and modulates its physiology. Here we present an effective anti-adhesive therapy against *Pseudomonas aeruginosa* that thereby blocks surface adaptation.

Advantages

Anti-attachment and anti-virulence drugs are known to reduce the development of resistance during anti-infective treatment. Our compound has the potential to address the prevention of infection by reducing the colonization by bacteria such as *P. aeruginosa*. It can be used in combination therapy with antibiotics to treat burn wounds and pneumonia, thereby enhancing

efficacy or reducing the required dosage, thereby minimizing the emergence of antibiotic-resistant clones.

Applications

- Treatment of *Pseudomonas aeruginosa* infections including wound and lung.
- Treatment of *Acinetobacter baumannii* infections.
- Prophylactic for susceptible patients, including individuals with cystic fibrosis, chronic obstructive pulmonary disease and diabetes.